We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Ultragenyx (RARE - Free Report) shares rallied 5.2% in the last trading session to close at $30.77. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 25.8% gain over the past four weeks.
Investor optimism is supported by Ultragenyx's growing portfolio of marketed rare disease therapies and a promising late-stage pipeline. Flagship products Crysvita, Dojolvi and Mepsevii continue to drive meaningful revenue growth, aided by Crysvita's expanded label and strong uptake of Dojolvi. Beyond its commercial portfolio, the company has multiple value-creating catalysts, including the FDA review of DTX401 for glycogen storage disease type Iawith a decision expected in August 2026, positive late-stage data for DTX301 in OTC deficiency announced in March and upcoming readouts for UX701 in Wilson disease and GTX-102 in Angelman syndrome in 2026. Investors view these commercial and pipeline milestones as positioning the company for sustained long-term revenue growth.
This biotechnology company is expected to post quarterly loss of $1.25 per share in its upcoming report, which represents a year-over-year change of -6.8%. Revenues are expected to be $185.77 million, up 11.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Ultragenyx, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RARE going forward to see if this recent jump can turn into more strength down the road.
Ultragenyx is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Tarsus Pharmaceuticals, Inc. (TARS - Free Report) , finished the last trading session 2.2% lower at $62.92. TARS has returned 8.1% over the past month.
Tarsus Pharmaceuticals' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.22. Compared to the company's year-ago EPS, this represents a change of +54.2%. Tarsus Pharmaceuticals currently boasts a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE - Free Report) shares rallied 5.2% in the last trading session to close at $30.77. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 25.8% gain over the past four weeks.
Investor optimism is supported by Ultragenyx's growing portfolio of marketed rare disease therapies and a promising late-stage pipeline. Flagship products Crysvita, Dojolvi and Mepsevii continue to drive meaningful revenue growth, aided by Crysvita's expanded label and strong uptake of Dojolvi. Beyond its commercial portfolio, the company has multiple value-creating catalysts, including the FDA review of DTX401 for glycogen storage disease type Iawith a decision expected in August 2026, positive late-stage data for DTX301 in OTC deficiency announced in March and upcoming readouts for UX701 in Wilson disease and GTX-102 in Angelman syndrome in 2026. Investors view these commercial and pipeline milestones as positioning the company for sustained long-term revenue growth.
This biotechnology company is expected to post quarterly loss of $1.25 per share in its upcoming report, which represents a year-over-year change of -6.8%. Revenues are expected to be $185.77 million, up 11.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Ultragenyx, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RARE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Ultragenyx is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Tarsus Pharmaceuticals, Inc. (TARS - Free Report) , finished the last trading session 2.2% lower at $62.92. TARS has returned 8.1% over the past month.
Tarsus Pharmaceuticals' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.22. Compared to the company's year-ago EPS, this represents a change of +54.2%. Tarsus Pharmaceuticals currently boasts a Zacks Rank of #3 (Hold).